Loading...
Loading...
BTAI| Name | Value |
|---|---|
| Revenues | 0.2M |
| Cost of Revenue | 1.2M |
| Gross Profit | -1.0M |
| Operating Expense | 14.3M |
| Operating I/L | -15.3M |
| Other Income/Expense | 1.6M |
| Interest Income | 0.6M |
| Pretax | -13.7M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -13.7M |
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience and immuno-oncology. Their drug re-innovation approach leverages existing approved drugs and big data to identify new therapeutic indices. Their commercial product, IGALMI, is a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar disorder. They also conduct clinical trials for other indications. Additionally, they are developing BXCL502 for chronic agitation in dementia and BXCL701 for aggressive forms of prostate cancer and advanced solid tumors. The company generates revenue through the commercialization of IGALMI and potential future products.
